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Objective: This experiment examined the feasibility of minimally invasive 
port-access mitral valve replacement via a 2.5 cm incision. Methods': The study 
evaluated valvular performance and myocardial functional recovery in six 
mongrel dogs after port.access mitral valve replacement with a St. Jude 
Medical prosthesis (St. Jude Medical, Inc., St. Paul, Minn.). Femoro-femoral 
cardiopulmonary b pass and a balloon catheter system for myocardial protec- 
tion with cardioplegic arrest (Heartport. Inc., Redwood City, Calif.) were used. 
The mitral valve was replaced through a2.5 cm port in the left side of the chest. 
and the animals were weaned from bypass. Cardiac function was measured 
before and at 30 and 60 minutes after bypass. Left ventricular pressure and 
electrical conductance volume were used to calculate changes in load-indepen- 
dent indexes of ventricular function. Results: Each procedure was successfully 
completed. Recovery of left ventricular function was excellent at 30 and 60 
minutes after bypass compared with the prebypass values for elastance I30 
minutes = 4 .04  + 0 .97  and 60 minutes = 4 .27  - 0.57 vs prebypass = 4.45 - 
0.96; p = 0.51) and for preload recruitable stroke work (30 minutes = 76.23 -+ 
4.80  and 60 minutes = 71.21  - 2 .99  vs prebypass = 71.23 -+ 3.75; p = 0.45). 
Preload recruitable work area remained at 96% and 85% of baseline at 30 and 
60 minutes (p = not significant). In addition, transesophageal chocardiogra- 
phy demonstrated normal prosthetic valve function, as well as normal regional 
and global ventricular wall motion. Autopsy revealed secure annular-sewing 
apposition and normal leaflet motion. Conclusions: These results suggest that 
minimally invasive mitral valve replacement using percutaneous cardiopulmo- 
nary bypass with cardioplegic arrest is technically reproducible, achieves 
normal valve placement, and results in complete cardiac functional recovery. 
Minimally invasive mitral valve replacement is now feasible, and clinical trials 
are indicated. (J Thorac Cardiovasc Surg 1997:113:1022-31) 
A S a result of recent advances in technology and instrumentation, the concepts of minimally inva- 
sive or less invasive surgery can be applied to a 
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variety of complex heart operations. The anticipated 
benefit to patients is the ability to provide all of the 
advantages of open cardiac surgical operations with 
decreased pain, morbidity, and recovery time. In a 
previous article, 1 we evaluated a system of cardio- 
pulmonary bypass (CPB) and myocardial protection 
with cardioplegic arrest using a catheter system (En- 
doCPB, Heartport, Inc., Redwood City, Calif.). In that 
study the catheter and cardioplegia delivery system 
were found to be as safe and effective as standard open 
chest CPB with cardioplegic arrest. In the present 
study we applied this CPB balloon catheter system to 
a canine animal model and used port-access technol- 
ogy (Heartport) to perform mitral valve replacement 
with a St. Jude Medical valve prosthesis (St. Jude 
Medical. Inc., St. Paul. Minn.). This was done both 
under direct vision and with the aid of video-thoracos- 
copy through a 2.5 cm left lateral thoracotomy using 
several conventional valve suturing techniques. 
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The purposes of this study were (1) to describe a 
port-access technique of minimally invasive mitral 
valve replacement and (2) to determine whether this 
technique of mitral valve replacement is technically 
reproducible and achieves normal valve placement 
and function, with preservation of myocardial func- 
tion after the operation. 
Materials and methods 
Study group, Six heartworm-free mongrel dogs (25 to 
30 kg) were supported with femoro-femoral CPB and had 
mitral valve replacement with a st. Jude Medical prosthe- 
sis via a 25 mm left lateral thoracotomy port. Each animal 
served as its own control in that baseline hemodynamic 
and load-independent measurements of cardiac perfor- 
mance were compared with the same measurements taken 
after the procedure. All animals were given humane care 
in compliance with the "Principles of Laboratory Animal 
Care" formulated by the National Society for Medical 
Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
Surgical preparation. All animals were initially anes- 
thetized with a 4% solution of thiamylal (0.5 mg/kg). They 
were maintained on a regimen of metocurine iodide (0.5 
mg/kg) and a mixture of isoflurane and oxygen after 
endotracheal intubation and placement on a mechanical 
ventilator. All animals were monitored throughout the 
entire procedure with electrocardiography and measure- 
ment of carotid arterial pressure (Koenigsberg Instru- 
ments, Inc., Pasadena, Calif.), pulmonary artery and cen- 
tral venous pressures with a pulmonary artery catheter 
(Arrow, Reading, Pa.), oxygen saturation by means of an 
external pulse oximeter, and carbon dioxide by means of a 
capnometer. Arterial blood gases and pH were kept in the 
normal range by adjusting inspired oxygen concentration 
and minute ventilation or by administering sodium bicar- 
bonate. Electrolyte and hematocrit levels were also mon- 
itored at appropriate intervals throughout the procedure. 
No blood transfusions were given. 
Technique of catheter placement. The technique of 
catheter placement for minimally invasive CPB has been 
described. 1 In brief, all Catheters were placed with the 
chest closed after systemic heparinization (100 U/kg) (Fig. 
1). A femoral venous catheter (17F cannula, model 58517, 
DLP, Inc., Grand Rapids, Mich.) was placed through aleft 
femoral venous eutdown and fluoroscopically guided 
(MCA 30 Ratheon, Tokyo, Japan) over a guide wire to a 
position just within the superior vena cava. The left 
femoral artery was cannulated with a femoral arterial 
catheter (14F, model 57414, DLP). Both catheters were 
then connected to the bypass pump (Shiley S-100A Bub- 
ble Oxygenator, Shiley, Inc., Irvine, Calif., and Pemco 
roller pump, model 5745, Pemco, Inc., Cleveland, Ohio) 
in a standard fashion. Venous return was aided by attach- 
ment of the return venous cannula to a centrifugal pump 
(Bio-pump, Medtronic Bio-Medicus, Eden Prairie, 
Minn.). Next, an endovascular pulmonary artery venting 
catheter (Endopulmonary Vent, Heartport) was inserted 
into the external jugular vein and guided into position 
over a flow-directed pulmonary artery balloon catheter by 
means of fluoroscopy. An endovascular aortic clamp 
(Endoaortic Clamp, Heartport) was positioned under 
fluoroscopic guidance via the contralateral femoral artery 
into the ascending aorta over a guide wire. Positioning of 
the balloon at the end of the endovascular ortic clamp in 
the aortic root was confirmed with instillation of a small 
aliquot of dilute radiopaque contrast medium (Hypaque 
sodium, Sanofi Winthrop Pharmaceuticals, New York, 
N.Y.) through the central lumen which communicates 
with the tip of the catheter positioned in the aortic root. 
The balloon was positioned so that it rested in the aorta 
without occlusion of the coronary ostia or aortic arch 
vessels. Antegrade cardioplegic solution was delivered 
through the central lumen of this catheter, which also 
acted as an aortic root vent. Aortic root pressure was 
monitored continuously through a third separate lumen. 
In the present study an additional catheter was inserted 
into the opposite xternal jugular vein and positioned into 
the coronary sinus over a guide wire with the aid of 
fluoroscopy (Fig. 2). This percutaneous coronary sinus 
catheter (Endosinus Catheter, Heartport) was used tO 
infuse retrograde cardioplegic solution and monitor cor- 
onary sinus pressure. 
CPB and delivery of eardioplegic solution. All animals 
were supported by total femoro-femoral CPB, cooled to a 
temperature of 20 ° C, and maintained on CPB at a flow 
rate of 50 ml/kg per minute. Arterial oxygen tension was 
kept above 70 mm Hg, and the mean arterial pressure on 
CPB was maintained at 60 mm Hg by adjusting bypass 
flow. Th e ascending aorta was occluded by inflation of the 
balloon at the end of the endovascular ortic clamp, and 
balloon pressure was monitored. Each animal received 
Freme's cardioplegic solution with oxygenated blood (ra- 
tio 4:1) cooled to 6°C in a BCD Plus Heat Exchanger 
(Shiley). Initially through the distal end of the endovas- 
cular aortic clamp an antegrade dose of 20 ml/kg high- 
potassium cardioplegic solution (20 to 24 mEq/L final 
concentration) was delivered to arrest the heart. Subse- 
quent doses of 10 ml/kg low-potassium ixture (8 to 12 
mEq/L final concentration) cardioplegic solution were 
given through the retrograde coronary sinus catheter, or 
via the antegrade route in the two animals in "which 
coronary sinus catheterization was not possible, at 15- 
minute intervals. All doses were given at a rate of at least 
75 ml/min and the infusion pressures were monitored. The 
hematocrit value during CPB remained above 25% in all 
cases. The pulmonary artery and the aortic root were 
vented throughout bypass and drained into the oxygenator 
reservoir. Aortic root pressure and pulmonary artery 
pressures were also monitored. At the conclusion of the 
procedure, the blood temperature was warmed to above 
35 ° C and the aorta was undamped. If necessary, the heart 
was defibrillated with external paddles. The heart was 
then allowed to rewarm to 37 ° C. Data acquisition was 
continued for 60 minutes after the completion of CPB. 
Technique of port-access mitral valve replacement. 
The mitral valve was replaced in this minimally invasive 
model with the use of specially designed instruments and 
an oval thoracic port (Heartport). Visualization was aided 
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Fig. 1. Schematic diagram outlining the percutaneous femoro-femoral bypass and endovascular balloon- 
catheter system used in this series of experiments. The venous and arterial cannulas are connected to the 
bypass pump. The endovascular ortic clamp is inserted through the femoral artery. The pulmonary artery 
vent is inserted though the left jugular vein and the percutaneous venting catheter is inserted through the 
right jugular vein. 
by video-assisted thoracoscopy. The animals were placed 
with the right side down at 15 degrees. A 2.5 cm incision 
was made in the left third or fourth intercostal space and 
the oval thoracic port was inserted (Fig. 3). An additional 
10 mm port was placed in the adjacent proximal intercos- 
tal space through which the thoracoscope was inserted. 
The animal was supported by CPB as previously described 
and the heart was arrested. A pericardiectomy was per- 
formed over the left atrial appendage and the left atrial 
appendage was grasped with a DeBakey grasper, triangu- 
lated, and suspended from the chest wall with suture 
material brought out through the chest wall and secured 
with hemostats. The left atrium was opened with a longi- 
tudinal incision. The mitral valve was inspected, and the 
anterior leaflet was excised. 
The mitral valve anulus was measured with a valve sizer, 
and the appropriate St. Jude Medical valve was sutured in 
place in a counterclockwise fashion by means of an atrial 
to ventricular technique. The sutures were placed through 
the prosthesis outside the chest cavity, and then the valve 
was lowered into proper position with the aid of a 
specially designed valve handle (Heartport), which could 
articulate and then be passed through the oval thoracic 
port. The sutures were tied either directly or, at times, 
with the aid of a specially designed knot pusher {Heart- 
port). The valve seating and leaflet motion were then 
inspected and tested. 
Air was removed from the heart as follows: (1) the 
animal was placed into the Trendelenburg position, (2) 
the ventricle was filled with blood by increasing radient 
from the pump, (3) the atrium was partially dosed with a 
continuous suture. (4) the heart was then gently massaged to
extrude air. (5) the lungs were gently ventilated, (6) the 
aortic root and pulmonary artery vents were placed on 
suction and the heart was filled with blood as the endovas- 
cular crossclamp was deflated, and (7) the atrium was fully 
dosed and the suture tied. After desiring was complete, the 
heart was defibrillated as necessary. 
Measurement of left ventrieular volume and pressure. 
Instantaneous left ventricular volumes were measured by 
means of the conductance method as previously de- 
scribed. 2-4 In brief, ventricular volume and pressure were 
measured with an integrated conductance volume and 
pressure micromanometer catheter for continuous on-line 
ventricular volume and pressure (Combicath. Sentron. 
Rhoden. The Netherlands). Calibration for absolute vol- 
ume was corrected by measuring parallel conductance 
before each set of data was acquired. 5 
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The conductance atheter was placed through the aortic 
valve and aligned along the long axis of the left ventricle, 
and the position was confirmed by fluoroscopy. A separate 
balloon catheter was placed into the inferior vena cava via 
a separate femoral vein puncture. When inflated, it was 
able to produce transient changes in preload. With left 
ventricular volume and pressure being recorded during 
changes in preload, a series of pressure-volume loops 
were generated and stored on a PC computer with the aid 
of a software package (Conduct-PC; Cardiodynamics bv, 
Leiden, The Netherlands) and the Sigma DF5 cardiac 
function analyzer (Cardiodynamics). 
Myocardial contractile data acquisition and analysis. 
Load-independent and parallel conductance measure- 
ments were made before CPB (baseline), 30 minutes after 
the completion of CPB, and 60 minutes after the comple- 
tion of CPB. Three sets of data were acquired uring each 
measurement period. Each set of data acquisition lasted 
30 seconds and was recorded over a range of left ventric- 
ular end-diastolic volumes produced by the transient (15 
second) caval occlusion. The method for measuring car- 
diac function was based on algorithms developed by other 
investigators. 6-9The indexes of regional eft ventricular 
systolic contractile function calculated were the preload 
recruitable stroke work (PRSW), the preload recruitable 
work area (PRWA), and maximal regional elastance. 
Pressure measurements. Aortic root and pulmonary 
artery pressure were recorded at 15-minute intervals 
during CPB. Antegrade and retrograde cardioplegia in- 
jection pressures were also measured and recorded. 
Echoeardiographic assessment of valve and heart func- 
tion. After each mitral valve replacement and after wean- 
ing from CPB, two-dimensional transesophageal chocar- 
diography (Hewlett-Packard Sonos 1000 with 5 MHZ 
biplane transesophageal probe, Hewlett-Packard Com- 
pany, Palo Alto, Calif.) with a color flow study was 
performed to assess prosthetic valve motion and valve 
seating and to identify any abnormal areas of flow accel- 
eration. Also, ventricular and septal wall motion were 
assessed. 
Statistical methods. Data were analyzed by the SPSS 
for Windows statistical software program (SPSS, Inc., 
Chicago, Ill.). All results are expressed as the mean _+ 
standard eviation. The statistical significance of changes 
in load-independent i dexes of ventricular function were 
compared by repeated-measures analysis of variance. Sig- 
nificance was determined at the 5% level. 
Results 
CPB, delivery of cardioplegic solution, and ven- 
tricular decompression. Six mongrel dogs were suc- 
cessfully supported by femoro-femoral CPB with the 
use of a balloon catheter system for aortic cross- 
clamping and protected cardioplegic arrest. Hemo- 
dynamic data are listed in Table I. All animals had 
mitral valve replacement with a St. Jude Medical 
prosthesis performed through a 2.5 cm thoracic port 
with left atrial exposure. All hearts arrested within 
90 seconds after institution of antegrade cardiople- 
Fig. 2. Roentgenogram illustrating proper position of the 
endovascular ortic clamp (EAC) in the ascending aorta 
with opacification of the balloon at the tip of the catheter. 
The endovascular coronary sinus catheter (ECS) is prop- 
erly positioned with the balloon inflated and opacified. 
Contrast material can be infused into the coronary sinus 
to confirm proper position. The endovascular pulmonary 
artery venting catheter (EPV) and the long venous can- 
nula (VC) are overlying the cardiac silhouette. 
gia. This was followed by retrograde cardioplegia 
(n = 4) or antegrade cardioplegia (n = 2) through- 
out the remainder of the procedure. 
In cases in which coronary sinus catheter injection 
of cardioplegic solution was used, the pressure 
averaged 32.5 _+ 3.1 mm Hg. On the other hand, 
antegrade cardioplegia injection pressures were 
slightly higher (39.7 +_ 5.1 mm Hg). In all cases 
adequate decompression of the heart was possible, 
with the average pulmonary artery and aortic root 
pressures remaining low throughout he period of 
cardioplegic arrest and cardiac venting (1.3 _+ 1.8 
mm Hg and 0 _+ 0.7 mm Hg, respectively). 
Global myocardial contractile function. When 
the instantaneous intracavitary left ventricular pres- 
sure was plotted against the ventricular volume, 
pressure-volume loops resulted. At baseline before 
the institution of CPB and at 30 minutes and 60 
minutes after the completion of CPB, myocardial 
function was measured, and the results are pre- 
sented in Figs. 4 to 6. The mean linear correlation 
coefficient for all these measurements was 
99%. There were no significant changes with 
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Fig. 3. The mitral valve is replaced through the l ft atrial appendage under direct vision and with the aid 
of thoracoscopy through a 25 mm oval thoracic port placed in the third or fourth intercostal space (ICS), 
The thoracoscope is introduced through aseparate 10 mm port placed in either the intercostal space above 
or below the oval port. 
Table I. Minimally invasive MVR operative data 
CPB duration (rain) 
Crossclamp time (rain) 
Heart rate baseline (beats/rain) 
Heart rate after MVR (beats/min) 
Aortic root vent pressure (ram Hg) 
PA vent pressure (mm Hg) 
Aortic injection pressure (mm Hg) 
CS injection pressure (ram Hg) 
EAC balloon pressure (mm Hg) 
Sinus rhythm after MVR 
88.3 _+ 13.2 
55.6 _+ 10.3 
108.3 -+ 12.1 
109.3 -+ 14.1 
0.0 _+ 0.7 
1.3 _+ 1.8 
39.7 + 5.1 
32.5 _+ 3.1 
475 _+ 33.5 
100% 
Hemodynamic data are expressed as the mean -+ standard deviation. MVR, 
Mitral valve replacement; CPB, cardiopulmonary bypass; PA, pulmonary 
a~te~; CS, coronary sinus; EAC, endovascular aortic lamp. 
respect to within-subject effects in the maximal 
elastance at both 30 and 60 minutes after the 
completion of CPB (30 minutes = 4.04 _+ 0.97 and 
60 minutes = 4.27 _+ 0.57 vs pre-CPB = 4.45 _+ 0.96; 
p = 0.51) (Fig. 4). There were also no significant 
changes in the PRSW (30 minutes = 76.23 _+ 4.80 
and 60 minutes = 71.21 _+ 2.99 vs pre-CPB = 
71.23 _+ 3.75;p = 0.45) (Fig. 5). PRWAs were 96% 
and 85% of baseline at 30 and 60 minutes after 
CPB, respectively (p = 0.40) (Fig. 6). The mean 
percentage standard deviations were 8% and 7% 
for the variables PRSW and PRWA, respectively, 
Power analysis of our experimental protocol re- 
vealed that with a power of 80% and a two-tailed 
t test at the level of 5%, we were able to detect a 
difference in myocardial function before and after 
CPB if the percentage difference was greater than 
12% for PRSW and greater than 10.5% for 
PRWA. 1° 
Echocardiography. Transesophageal echocardi- 
ography performed after the procedure demon- 
strated normal valve leaflet function in all cases. No 
areas of abnormal flow acceleration were seen, and 
all valves exhibited normal prosthetic regurgitation 
(Fig. 7, A and B). All valves appeared to be seated 
properly. In addition, ventricular wall motion and 
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Fig. 4. Maximal elastance (Emax) of the end-systolic pressure-volume relationship represented asboxplots 
of the mean values before and after CPB. NS, Not significant, p = 0.51. 
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BASELINE 30 MIN POST-CPB 60 MIN POST-CPB 
p=NS 
Fig. 5. PRSW of the end-diastolic pressure-volume relationship represented as boxplots of the mean 
values before and after CPB. NS, Not significant, p = 0.45. 
septal motion appeared normal in each region of the 
heart in all cases. 
Autopsy. After completion of the procedure and 
acquisition of all data, the animals were put to death 
and an autopsy was performed. Sutures appeared to 
be appropriately placed in the anulus and securely 
tied, demonstrating secure annular-sewing apposi- 
tion with normal valve leaflet motion. The myocar- 
dium had no areas of gross hemorrhage or infarct. 
The aortic root of all animals appeared normal. The 
coronary sinus had no areas of gross hemorrhage or 
damage, and in the two cases that were not amena- 
ble to cannulation, the ostia were noted to be small. 
Discussion 
Previous studies by Stevens and coworkers 11' 12 
and from our laboratory 1 have demonstrated an 
effective method of performing closed chest CPB 
and cardioplegic arrest with endovascular aortic 
occlusion. On the basis of that capability, this study 
was designed to apply this technology and evaluate a
method of port-access minimally invasive mitral 
valve replacement. As originally proposed by Pom- 
pili and colleagues, 13this study describes a closed 
chest method of mitral valve replacement in a 
canine model, without the need for median sternot- 
omy or a large thoracotomy. The results from both 
1028 Schwartz et al. 
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Fig. 6. Myocardial contractile function quantified by PRWA as a percentage ofthe mean pre-CPB value. 
p = 0.40. 
the Stanford and the New York University labora- 
tories suggest that this technique is highly reproduc- 
ible. 
Certainly, when one is proposing that a major 
cardiac procedure such as mitral valve replacement 
be performed in a minimally invasive manner, the 
chief concerns are as follows: (1) Is the procedure 
safe, reproducible, and comparable with the current 
standard "open" procedure? (2) Are exposure and 
visualization adequate? (3) Do the instrumentation 
and technology allow proper valve suture place- 
ment, valve seating, and suture tying? (4) Is the final 
functional result, both in terms of valvular function 
and myocardial functional recovery, adequate? 
On the basis of the present results in this experi- 
mental canine model, the answer to all of these 
questions is yes. The mitral valve was successfully 
replaced in six mongrel dogs. Exposure was ade- 
quate in every case, and the instrumentation allowed 
adequate valve placement and seating. An impor- 
tant point in assessing the efficacy of any new cardiac 
surgical technique is to determine the technique's 
potential for minimizing or worsening myocardial 
damage during aortic crossclamping. In this study, 
all measurements of global myocardial perfor- 
mance, including the PRSW, PRWA, and the max- 
imal elastance, were equivalent before and after 
valve replacement. Likewise, the valve functioned 
properly in every case. Thus results of the minimally 
invasive port-access technique of mitral valve re- 
placement appear to be equivalent in every way to 
the results obtained after standard mitral valve 
replacement. 
A secondary goal of this study was to determine 
whether percutaneous endovascular delivery of car- 
dioplegic solution could be done in a retrograde 
fashion, through the coronary sinus, as well as with 
the previously described antegrade technique} Suc- 
cessful placement of the percutaneous retrograde 
coronary sinus catheter was possible in four dogs. 
Difficulty in cannulating the coronary sinus in one 
dog may have been due to the relatively small size of 
the opening of the sinus, as noted at autopsy. In the 
final case, proper positioning of the coronary sinus 
catheter was verified, but the cardioplegic solution 
injection pressure was above 50 mm Hg and further 
retrograde injection was aborted. In both of the 
cases in which retrograde administration of car- 
dioplegic solution was not successful, the technique 
was converted to antegrade delivery and myocardial 
protection was equally effective. 
Likewise, decompression f the heart by the en- 
dovascular aortic catheter and the endovascular 
pulmonary artery vent was highly successful, allow- 
ing a bloodless operating field. This is thought o be 
extremely important, because a dry field is essential 
with a limited exposure technique. 
The primary limitation of this study is that a 
relatively healthy canine model differs in many 
respects from a human patient with heart disease, 
Nevertheless, this study attempted to simulate the 
technique required for removing a diseased valve by 
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Fig. 7. A, Representative diastolic frame from a transesophageal chocardiogram demonstrating ormal 
mitral prosthetic valvular flow (arrow). B, Representative systolic frame from a transesophageal chocar- 
diogram demonstrating minimal mitral regurgitation (arrow), which is physiologic for a St. Jude Medical 
prosthesis. No perivalvular leak or areas of abnormal f ow acceleration are present. LA, Left atrium; LV, 
left ventricle). 
excising the anterior mitral leaflet in every case 
while preserving the posterior leaflet. Although the 
shape of the canine chest differs from that of 
humans in that the human chest cavity is much 
broader and wider, 11 this study nevertheless demon- 
strates the overall feasibility of a minimally invasive 
port-access technique using newly designed technol- 
ogy (Heartport). In human beings a left lateral or 
third or fourth intercostal space incision may give 
similar excellent access to the left atrium. Also, on 
the basis of preliminary clinical trials, a limited right 
anterior thoracotomy may provide excellent access. 
Use of innovative ndovascular access devices in 
combination with peripheral CPB has provided the 
technologic advance necessary to make minimally 
invasive port-access mitral valve replacement a re- 
ality. The findings of this study demonstrate that 
port-access mitral valve replacement is technically 
feasible, reproducible, and effective. The overall 
results demonstrate hat the endovascular CPB sys- 
tem (Heartport) was able to provide complete aortic 
occlusion, adequate cardioplegic delivery and myo- 
cardial protection, effective myocardial venting, and 
excellent return of myocardial function. The impli- 
cations of these findings are significant, because the 
methods used in this study may set the groundwork 
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for the development of less invasive mitral valve 
procedures in patients. Clinical trials with minimally 
invasive mitral valve repair or replacement using the 
port-access technique are now in progress. 
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Discuss ion 
Dr. W. R. Eric Jamieson (Vancouver, Bl~tish Columbia, 
Canada) [read by the moderator in Dr. Jamieson's ab- 
sence]. Dr. Schwartz and associates have demonstrated 
that minimally invasive mitral valve replacement is tech- 
nically feasible with port-access technology. They have 
shown that the procedure can be performed with accept- 
able ischemic and CPB times. Maximal elastance and 
PRSW have demonstrated preservation of myocardial 
function. The procedure is complicated by six vascular 
access maneuvers to accomplish CPB, monitoring, endo- 
vascular aortic occlusion, cardioplegic delivery, and cham- 
ber venting. Three of these access maneuvers require 
fluoroscopy and radiopaque dye for placement of the 
endovascular ortic clamp. 
I have not performed the procedure with port-access 
technology. I have considerable experience with mitral 
valve replacement in a sheep model for anticalcification 
studies of new technology. These procedures were per- 
formed through a limited anterior thoracotomy in the left 
fourth intercostal space. 
I have several comments and a few questions for the 
authors. The ability to control factors that are of potential 
risk to the animal and subsequent future patients is of 
most concern. There is a definite need for external 
defibrillation, as was used in the experimental endeavor. 
These procedures are satisfactory but must be totally 
acceptable for clinical use. I have recently observed Dr. 
Alain Carpentier's video presentation of mitral valve 
repair using minimally invasive techniques. The procedure 
was difficult and defibrillation was a problem. The pa- 
tient's course in the hospital was not shortened by the 
procedure. 
It has been stated that the concept of minimally invaswe 
surgery is patient driven. I am concerned that adequately 
informing the patients of the lack of ability to control 
special compromising circumstances may reduce patient 
enthusiasm. There are several potential devastating com- 
plications with the procedure, such as (1) atheromatous 
embolization with femoral cannulation and retrograde 
flow and (2) displacement of the endovascular aortic 
clamp with compromise of cerebral and coronary perfu- 
slon. 
My questions are few. What is the total potential length 
of the procedure with extensive vascular access? 
Dr. Schwartz. The study presented here is an animal 
experiment. However. I can outline briefly the length of 
the procedure both for this animal study and for clinical 
studies in human beings. The approach and catheter 
placement are different and. most important, he scope of 
the procedures performed is more extensive with respect 
to our clinical trial. In these animal studies, it took about 
half an hour to place all of these catheters with the 
exception of the retrograde coronary sinus catheter. 
Whereas this was particularly difficult to place in this 
canine model, in human studies placement was not at all 
difficult, and all attempts to date have been successful. As 
presented in this animal study, it took an average of 88 
minutes to perform this procedure with CPB, after which 
weaning from CPB and collection of the data lasted about 
another 60 to 70 minutes. 
In our clinical experience, we, along with Stanford 
University, are part of a phase I clinical trial using this 
port-access system for mitral valve repair and replace- 
ment. At New York University Medical Center we have 
successfully repaired and/or replaced the mitral valve in 
seven patients. The phase I trial has been completed and 
has been resubmitted to the Food and Drug Administra- 
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tion. The complexity of the procedure really determines 
how much time it takes to complete it. During this phase 
I trial, we performed not only mitral valve replacement 
but mitral valve repairs. Therefore, how long it would take 
in the clinical setting is quite variable. 
Dr. Jamieson. Do you operate with lead protection for 
the need of repeat fluoroscopy? 
Dr. Schwartz. In these first few cases, we operated with 
lead protection throughout the procedure. After the sixth 
case everybody was quite tired from the lead, but in the 
beginning, with our increased enthusiasm, we did not feel 
the need to remove the lead. It did not bother us very 
much, 
Dr. Jamieson. Do you think there will be a medicolegal 
issue with concern over the risk of the procedure, induced 
complications, and lack of ready access for control of 
infrequent but uncontrollable complications from port- 
access techniques? 
Dr. Schwartz. I cannot really answer that question at 
this time, but I think a sufficient safety net is in place. As 
was mentioned in the discussion, there was some concern 
over placement of the balloon, slippage of the balloon, 
deflation of the balloon, and occlusion of the head vessels. 
Many safety mechanisms are built into the procedure. For 
example, we monitor both arterial and aortic root pres- 
sures to look for a difference in pressure to help determine 
whether the balloon has slipped. We also monitor the 
balloon pressure throughout the entire procedure. If there 
is a concern, we use fluoroscopy to reevaluate the position 
of the catheter. The visual access to the mitral valve in 
these clinical cases was excellent, so I am not sure that 
there would be much of a concern over that aspect. 
Dr. Jamieson. I congratulate you on an elegant exper- 
imental study demonstrating feasibility in minimally inva- 
sive mitral valve surgery. Several questions remain: Where 
do we go from here? Which patients do we select? How do 
we train cardiac surgeons? What is the cost/benefit ratio 
of the technique? Do we need a controlled randomized 
trial before embarking on general availability of port- 
access equipment to the marketplace? 
Dr. D. Craig Miller (Stanford, Calif.). Dr. Schwartz, 
who did the calculations of left ventricular systolic me- 
chanics? 
Dr. Schwartz. I did the calculations. 
Dr. Miller. You said that you used a conductance 
catheter to measure left ventricular volume, yet your 
depiction of systolic elastance PRSW or PRWA are all 
measured per centimeter and not per milliliter. I assume 
your conductance catheter did not work or you did not 
believe it, which is more often the case, and you relied 
instead on echo dimension. Can you amplify? 
Dr. Schwartz. Maximal elastance was measured in 
milliliters. This was a typographical error on the illustra- 
tion. The illustration showing PRSW is discussing volume. 
This is depicted in centimeters cubed for the preload, so I 
believe that is correct. 
Dr. Julian Smith (Melbourne, Australia). We have con- 
ducted similar studies in our laboratory with a couple of 
variations. We have been able to successfully do the 
procedure through a right thoracotomy in the dog model, 
just further mimicking the human situation. We have also 
done a series of deairing studies looking for residual 
cardiac air and the incidence of embolization of air to the 
periphery, and we have found a very low incidence and 
very satisfactory results with the deairing techniques we 
have used. 
Dr. William Brenner (Hackensack, N.J.). I saw the 
video at meeting of the New York Thoracic Society and it 
was very impressive. How much contrast material would 
you estimate is used in the human clinical situation? Are 
you concerned, in the high-risk elderly patient, about the 
synchronous effect of contrast material plus CPB insult to 
the kidneys? 
Dr. Schwartz. The amount of contrast material is 
negligible compared with that used in other vascular 
angiographic techniques. In fact, a lot of the contrast 
material is actually given into the balloon catheters. I 
would estimate that less than 20 to 25 ml of a 50% 
solution of radiopaque contrast is given in total. 
